RCT and VTU Technology Partner to Offer Custom Glycoprotein Production in Pichia GlycoSwitch
Tucson, Arizona and Grambach, Austria – Dec 03, 2014
VTU Technology and Research Corporation Technologies (RCT) announced today that they have entered into a development and commercialization agreement for VTU to combine both companies´ Pichia pastoris protein production technologies. Pichia GlycoSwitch® – a new expression system for the production of glycoproteins with human-like glycosylation patterns – and VTU´s yield enhancing Pichia pastoris expression platform are now available in one package from VTU. This unique combination of technologies acting synergistically is of great benefit for customers as it leads to a high performance production platform for recombinant glycoproteins with superior product yields and uniform Man5 – or other human-like glycoforms.
Under the terms of the agreement, RCT grants VTU Technology access to RCT´s Pichia GlycoSwitch® expression system for combination with VTU´s in-house high-yielding Pichia platform featuring different proprietary technologies such as AOX1 promoter libraries suited for both methanol-induced and methanol-free production. VTU Technology is now offering the combined technology suite as part of the company´s expression strain and corresponding bioprocess development contract services portfolio.
“We are delighted to offer Pichia GlycoSwitch® engineered with our broad portfolio of Pichia tools in this partnership with RCT and I am convinced that our yield enhancing technologies will give GlycoSwitch® an exciting extra edge for the production of glycoproteins with Man5 – or other human-like glycoforms”, states Thomas Purkarthofer, Ph.D., Head of Business Development of VTU Technology.
“Our partnership with VTU Technology brings together two technologies that will enable customers to uniquely tailor the glycosylation of their target protein and explore new biological functions. We are looking forward to working with VTU Technology to expand the potential of proteins manufactured in Pichia GlycoSwitch®”, states Kurt R. Gehlsen, Ph.D., Vice President and CSO of Research Corporation Technologies, Inc.
For more information:
Thomas Purkarthofer, Ph.D.
VTU Technology GmbH
Phone: +43 316 4009 4017
Kurt R. Gehlsen, Ph.D.
Research Corporation Technologies